标的净资产为负 明德生物3570万元收购事项遭疑

Core Viewpoint - Mingde Biological is planning two acquisitions within a month, including a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. for 35.7 million yuan, despite Hunan Lanyi's negative net assets and consecutive losses [1][2]. Group 1: Acquisition Details - The acquisition of Hunan Lanyi aims to enhance synergy and core competitiveness, focusing on complementary industry chains to improve comprehensive service capabilities [1][2]. - Hunan Lanyi, established in September 2020, specializes in IVD instruments and reagents, recognized as a national high-tech enterprise and a "little giant" in specialized fields [2]. - The acquisition structure includes Mingde acquiring 51% of Hunan Lanyi, while related parties will hold an additional 20%, with plans for full control if performance targets are met [2][3]. Group 2: Financial Performance and Projections - Hunan Lanyi reported a net asset of -62.42 million yuan and consecutive losses of 20.68 million yuan in 2024 and 23.98 million yuan in the first three quarters of 2025 [1]. - Mingde Biological's projected net profit for 2025 is expected to decline by 75.85% to 83.9%, ranging from 12 million to 18 million yuan, primarily due to decreased investment income and increased credit impairment losses [5]. - The financial performance of Wuhan Bikaier, another target for acquisition, shows stable revenue and profit, with 2023 revenues of 168 million yuan and net profit of 12.64 million yuan [4].